Dr. Andrew Satterlee is at the forefront of developing innovative platforms for functional precision medicine, a re-emerging strategy that is pivotal in accelerating pre-clinical drug testing and guiding clinical decisions, particularly in cancer treatment. His work focuses on maintaining patient tumor tissues ex vivo for direct therapeutic testing, moving beyond traditional stained microscope slides or genetic analyses. Dr. Satterlee has been instrumental in the development of an organotypic brain slice culture (OBSC)-based platform, coupled with a multi-parametric algorithm, which enables rapid engraftment, treatment, and analysis of uncultured patient brain tumor tissues and patient-derived cell lines. His current research is expanding to include living tissue substrates from other organs, utilizing the advanced capabilities of the Precisionary Compresstome. In this webinar, Dr. Satterlee will share his insights and recent advancements, offering a detailed exploration of how these methods are shaping the future of personalized medicine.

In this webinar, Dr. Satterlee will will help you:

  • Understand the importance of functional drug testing in accelerating pre-clinical drug development.
  • Explore how organotypic brain slice cultures can maintain uncultured patient tumor tissues ex vivo, preserving their physiological relevance.
  • Differentiate between the Precisionary Compresstome and a standard vibratome, highlighting key advantages in tissue slicing.
  • Discover how the Precisionary Compresstome enables the generation of living tissue substrates from various organs, advancing research in functional precision medicine.